- +91 8471002000
- Messenger
Immunotherapy
Pembrolizumab
Pembrolizumab Injection
Injection
Brand name: Keytruda Manufacturer: Merck & Co., Inc.
Pembrolizumab Dose: 200mg via IV infusion every 3 weeks
Pembrolizumab is a groundbreaking treatment approved for combating various cancer types such as melanoma, non-small cell lung cancer, head and neck squamous cell carcinoma, classical Hodgkin's lymphoma, urothelial carcinoma, and gastric and esophageal tumors. Particularly effective in cases with microsatellite instability or impaired mismatch repair, this innovative therapy bolsters the immune system's ability to efficiently attack and destroy cancer cells.
Pembrolizumab emerges as a cutting-edge immunotherapy treatment, igniting the patient's immune system to recognize and eliminate malignant cells. This innovative approach disrupts the PD-1 protein pathway that cancers exploit to evade immune attacks, thereby strengthening the body's innate defenses. As a versatile weapon in the arsenal against various cancers, pembrolizumab heralds a unique epoch in tailor-made cancer management tactics.
Resistance to pembrolizumab injection materializes through alterations in the molecular makeup of cancer cells, hindering the disruption of immune checkpoints and limiting T-cell engagement. Consequently, cancer antigen presentation declines, while inhibitory components strengthen. This weakens pembrolizumab's efficacy, diminishing its ability to combat tumor progression effectively.
Pembrolizumab injection administration may be accompanied by an array of unforeseen side effects, including persistent lethargy, continuous cough, feelings of nausea, and exacerbated dermatological issues. Certain cases may witness the occurrence of serious events, such as the body's self-attack on organs, pulmonary irritation, liver discomfort, or intense injection-related difficulties. Continuous vigilance is crucial to ensure swift identification and handling of these potential hazards.
Pembrolizumab, a powerful cancer treatment, can be proficiently combined with diverse medications based on the precise cancer type. In cases of non-squamous NSCLC, it is typically amalgamated with pemetrexed and platinum-based chemotherapy drugs like cisplatin or carboplatin. Furthermore, the FDA endorses the simultaneous use of pembrolizumab and axitinib for tackling advanced RCC. Collaborating with a healthcare specialist is crucial to design an appropriate treatment strategy.
Pembrolizumab Injection avg price: ₹61,500 in India. The above price is specific for Indi, Karnataka, India
WhatsApp us